Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study

  title={Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study},
  author={Marianne Canonico and Agn{\`e}s Fournier and Laure Carcaillon and Val{\'e}rie Oli{\'e} and Genevi{\`e}ve Plu-Bureau and Emmanuel Oger and Sylvie Mesrine and Marie‐Christine Boutron‐Ruault and Francoise Clavel-Chapelon and Pierre-Yves Scarabin},
  journal={Arteriosclerosis, Thrombosis, and Vascular Biology},
Objective—Oral estrogen therapy increases venous thromboembolism risk among postmenopausal women. Although recent data showed transdermal estrogens may be safe with respect to thrombotic risk, the impact of the route of estrogen administration and concomitant progestogens is not fully established. Methods and Results—We used data from the E3N French prospective cohort of women born between 1925 and 1950 and biennially followed by questionnaires from 1990. Study population consisted of 80308… 

Tables from this paper

Hormone therapy and recurrence of venous thromboembolism among postmenopausal women

Oral but not transdermal estrogens are associated with a higher risk of recurrent VTE among postmenopausal women, providing further epidemiological evidence that transder mal estrogens may be safe with respect to VTE risk.

Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women

Transdermal estrogens may improve substantially the benefit/risk ratio of postmenopausal hormone therapy and should be considered as a safer option, especially for women at high risk for VTE.

Progestogens and venous thromboembolism in menopausal women: an updated oral versus transdermal estrogen meta-analysis

  • P. Scarabin
  • Medicine, Biology
    Climacteric : the journal of the International Menopause Society
  • 2018
Clinical findings emphasize the safety advantage of transdermal estrogen combined with progesterone and support the current evidence-based recommendations on HT, especially in women at high VTE risk.

Postmenopausal Hormone Therapy and Risk of Stroke

The findings suggest that transdermal estrogens might be the safest option for short-term hormone therapy use, and both route of estrogen administration and progestogens were important determinants of IS.

Progestogens and venous thromboembolism among postmenopausal women using hormone therapy.

Menopausal hormone therapy and venous thromboembolism

  • M. Binkowska
  • Medicine, Biology
    Przeglad menopauzalny = Menopause review
  • 2014
Among hormonal preparations which are commercially available in Poland, the combination of transdermal estradiol with oral dydrogesterone appears to be the optimum choice, as it does not elevate the risk of VTE (compared to patients not using MHT), and dydrosterone seems to beThe progestagen of choice.

Estrogen and progestogen effect on venous thromboembolism in menopausal women

  • D. ArcherE. Oger
  • Medicine
    Climacteric : the journal of the International Menopause Society
  • 2012
Oral hormone therapy has been used principally for management of menopausal symptoms and transdermal estrogens have not been used as extensively in the United States but have a significant use in Europe.

Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy

This large matched-cohort study based on real-world data suggests that women receiving transdermal ET have significantly lower incidences of CVD events compared with those receiving oral ET, and that they also incur lower healthcare costs.



Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study

Oral but not transdermal estrogen is associated with an increased VTE risk, and data suggest that norpregnane derivatives may be thrombogenic, whereas micronized progesterone and pregnane derivatives appear safe with respect toThrombotic risk.

Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism

The results show that the longer exposure to endogenous estrogen is associated with an increased VTE risk.

Postmenopausal Estrogen Replacement and Risk for Venous Thromboembolism

The venous thromboembolism risk with postmenopausal estrogen replacement therapy is estimated using a meta-analysis of eligible studies and fixed-effects and random-effects models using the Bayesian data analytic framework.

Hormone replacement therapy and risk of venous thromboembolism: population based case-control study.

Current use of hormone replacement therapy was associated with a higher risk of venous thromboembolism, although the risk seemed to be restricted to the first year of use.

Venous thrombosis and conjugated equine estrogen in women without a uterus.

An early increased VT risk is associated with use of estrogen, especially within the first 2 years, but this risk increase is less than that for estrogen plus progestin.

Estrogen plus progestin and risk of venous thrombosis

Estrogen plus progestin therapy was associated with doubling the risk of venous thrombosis and the risks associated with age, overweight or obesity, and factor V Leiden were increased.

Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis.

The finding that conjugated equine estrogen but not esterified estrogen was associated with venous thrombotic risk needs to be replicated and may have implications for the choice of hormones in perimenopausal and postmenopausal women.

Breast cancer risk in relation to different types of hormone replacement therapy in the E3N‐EPIC cohort

The results suggest that, when combined with synthetic progestins, even short‐term use of estrogens may increase breast cancer risk, and Micronized progesterone may be preferred to synthetic progESTins in short-term HRT.